: The UCSD CD4 Collaborative Clinical Trials Unit (CTU) will bring together six dynamic and diverse Clinical Research Sites (CRSs) that are well prepared to respond to the research priorities of the NIAID HIV/AIDS clinical research networks. Our CTU brings together the scientific expertise and experience required to conduct a broad variety of complex clinical trials in adults, adolescents, children and pregnant women in the areas of HIV therapeutic interventions aimed at cure, functional cure and eradication of HIV; new and novel antiretroviral drug development; HIV-related co-infections and comorbidities, including opportunistic infections and other end organ diseases; treatment and prevention of tuberculosis (TB) in HIV co-infected and TB mono-infected individuals; treatment and cure of viral hepatitis in co-infected and mono-infected individuals; biomedical and behavioral interventions to reduce or prevent HIV transmission (including pre-exposure prophylaxis, post-exposure prophylaxis and vaccine prevention strategies) in high risk populations, including pregnant women; and in the pathogenesis of HIV disease, including viral persistence, latent reservoirs, viral and vaccine immunology, and vaccine development. Through our CD4 Collaborative CTU we will address the following specific aims (briefly summarized here):
Specific Aim 1 (Innovative Science Infrastructure): Provide scientific expertise and efficient, flexible infrastructure to develop new strategies to improve the prevention and treatment of HIV infection within the context of the following NIAID Clinical Research Networks on: a) Therapeutics for HIV/AIDS and HIV associated Infections in Adults; b) HIV/AIDS and HIV-associated Infections in Pediatric and Maternal Populations; c) Integrated Strategies to Prevent HIV Infection; d) Vaccines to Prevent HIV Infection.
Specific Aim 2 (Effective Scientific Leadership): Provide excellent, effective leadership in administrative coordination and scientific participation within the CTU, across the CRSs, within communities served by the CTU, and across the clinical research networks in which our CTU will participate.
Specific Aim 3 (Effective Fiscal Management and Performance): Effectively manage all financial and infrastructure resources, and oversee, evaluate and assure exemplary performance of all components.
Specific Aim 4 (Community Engagement): Engage and partner with affected communities to shape network scientific agendas and to recruit, enroll and retain ideal research trial participant in network studies.

Public Health Relevance

The UCSD CD4 Collaborative Clinical Trials Unit (CTU) brings together six dynamic Clinical Research Sites in the U.S., sub-Saharan Africa, and India, with a proven track record of significant research into the pathogenesis and treatment of HIV and its complications. Our proposed CTU has the expertise, experience, infrastructure, and access to racially and ethnically diverse adult, adolescent and pediatric patient populations to make valuable contributions to the research priorities of the NIAID clinical research networks.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069432-09
Application #
8784154
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Adedeji, Bola
Project Start
2007-02-01
Project End
2020-11-30
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
9
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
MacBrayne, Christine E; Marks, Kristen M; Fierer, Daniel S et al. (2018) Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother 73:2112-2119
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Riddler, Sharon A; Zheng, Lu; Durand, Christine M et al. (2018) Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. Open Forum Infect Dis 5:ofy242
Shivakoti, Rupak; Ewald, Erin R; Gupte, Nikhil et al. (2018) Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial. Clin Nutr :
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS 32:583-593
Robertson, Kevin R; Jiang, Hongyu; Kumwenda, Johnstone et al. (2018) HIV Associated Neurocognitive Impairment in Diverse Resource Limited Settings. Clin Infect Dis :
Erlandson, Kristine M; MaWhinney, Samantha; Wilson, Melissa et al. (2018) Physical function improvements with moderate or high-intensity exercise among older adults with or without HIV infection. AIDS 32:2317-2326
Taiwo, Babafemi O; Marconi, Vincent C; Berzins, Baiba et al. (2018) Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis 66:1794-1797
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Palumbo, Philip J; Fogel, Jessica M; Hudelson, Sarah E et al. (2018) HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr 77:484-491

Showing the most recent 10 out of 288 publications